press coverage

January 30, 2020

Financial Times : Read the article detailing Exscientia's work on the first AI-designed drug to enter clinical trials.

News Coverage
Financial Times

AI-designed drug to enter clinical trials for first time.

Download and Read full article here: pdf

"A drug molecule invented entirely by artificial intelligence is set to enter human clinical trials for the first time, marking a critical milestone for the role of machine learning in medicine. The new compound, which has been designed to treat patients with obsessive-compulsive disorder, was developed by Oxford-based AI start-up Exscientia in collaboration with the Japanese pharmaceutical firm Sumitomo Dainippon Pharma."